Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2013
10/30/2013EP2655418A2 Anti-mesothelin antibodies and immunoconjugates
10/30/2013EP2655415A2 Tri-variable domain binding proteins and uses thereof
10/30/2013EP2655413A1 Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
10/30/2013EP2655403A1 Vaccines with live bacterial isolates for systemic administration
10/30/2013EP2655402A1 Oprf/i agents and their use in hospitalized and other patients
10/30/2013EP2655389A2 Compounds
10/30/2013EP2654793A2 Methods and compositions for wound treatment
10/30/2013EP2654792A2 Half immunoglobulin binding proteins and uses thereof
10/30/2013EP2654790A1 Modified antibody with improved half-life
10/30/2013EP2654789A1 Antibodies against human cd39 and use thereof
10/30/2013EP2654788A1 Gas-filled microvesicles for use as vaccine
10/30/2013EP2654787A1 Modified influenza hemagglutinin proteins and uses thereof
10/30/2013EP2654786A1 Adenoviral vector-based dengue fever vaccine
10/30/2013EP2654785A1 Enhanced immune response in bovine species
10/30/2013EP2654784A2 Stable immunogenic compositions of staphylococcus aureus antigens
10/30/2013EP2654783A1 Recombinant mycobacterium as a vaccine
10/30/2013EP2654782A2 Methods and compositions of protein antigens for the diagnosis and treatment of toxoplasma gondii infections and toxoplasmosis
10/30/2013EP2654781A1 Anti-p-selectin antibodies and methods of their use and identification
10/30/2013EP2654780A1 Active protease-resistant antibody fc mutants
10/30/2013EP2654779A1 Liposomal formulation of nonglycosidic ceramides and uses thereof
10/30/2013EP2654778A1 Vaccines based on peptides of the complement protein c5a
10/30/2013CN1922199B CA6 antigen-specific cytotoxic conjugate and methods of using same
10/30/2013CN103380146A Lipidated polyepitope vaccines
10/30/2013CN103379916A Respiratory syncytial virus vaccine
10/30/2013CN103379903A Process for preparing nanoparticles of two polyamino acids of opposite charge, one of the two of which is in charge surplus
10/30/2013CN103374580A Enterovirus 71 (EV 71) Fuyang strain and cDNA (deoxyribonucleic acid) infectious clone of attenuated strain of enterovirus 71 (EV 71) Fuyang strain as well as application of enterovirus 71 (EV 71) Fuyang strain
10/30/2013CN103374576A Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
10/30/2013CN103374552A PHF 8 (Plant Homedomain Finger Protein 8) protein fragment as well as prokaryotic expression and purification method and antibody thereof
10/30/2013CN103374549A Novel EV71 virus strain and application thereof
10/30/2013CN103374547A Method for preparing purified foot-and-mouth disease vaccine
10/30/2013CN103374074A Anti-CD25 single-chain antibody
10/30/2013CN103374073A Human derived monoclonal antibody for identifying activated integrin alpha 4 beta 7
10/30/2013CN103374072A Preparation of anti-Mac-2BP humanized antibody
10/30/2013CN103374071A Preparation of anti-DERLIN-1 humanized antibody
10/30/2013CN103374070A Anti-rabies-virus combination molecule 2F5
10/30/2013CN103374069A Anti-rabies-virus combination molecule 2E1
10/30/2013CN103372217A Polymer nano carrier preparation as well as preparation method and application thereof
10/30/2013CN103372213A Application of inhibitors of phospholipid scramblases (plscrs) for preparing medicine for the prophylactic or therapeutic treatment of cancers
10/30/2013CN103372209A Application of antibody of gp96 protein in preparation of cancer cell inhibitor
10/30/2013CN103372208A Application of morindae radix extract in preparation of immunologic adjuvant
10/30/2013CN103372207A DNA vaccine resisting multi-type avian influenza virus and composition thereof
10/30/2013CN103372206A Vaccines against chlamydial infection
10/30/2013CN103372205A Preparation method of tumor dendritic cell vaccine sensitized by glycosylated MUC1 (mucoprotein 1) antigen
10/30/2013CN103372204A External xenoliths vaccine combined dendritic cell cytokine induced killer (DC-CIK) new technology for cancer therapy
10/30/2013CN103372203A Antigen composition, preparation method and application of antigen composition and tumour vaccine
10/30/2013CN102924600B Death receptor-5 agitated polyvalent antibody and application thereof in preparation of anti-tumor medicines
10/30/2013CN102757483B Recombinant adenovirus for expressing porcine teschovirus type 8 VP1 protein and application thereof
10/30/2013CN102671192B Human diploid cell rabies vaccine and preparation method thereof
10/30/2013CN102614508B Virus split deactivation method for human influenza virus split vaccine
10/30/2013CN102559610B Recombined duck virus enteritis viral vaccine strain CCTCC for expressing bird flu virus hemagglutinin (HA) gene (rDEVus78Ha) as well as establishing method and application thereof
10/30/2013CN102552897B Prophylactic VLP (Virus-like Particle) vaccine for cervical carcinoma
10/30/2013CN102219853B Anti-H5N1 type bird flue virus vicuna VHH heavy chain antibody as well as preparation method and application thereof
10/30/2013CN102219837B Recombinant full-length A-type botulinum toxin mutant vaccine
10/30/2013CN102215865B Methods for purification of viruses
10/30/2013CN102180971B Recombinant beta-amyloid peptide B cell epitope polypeptide chimeric antigen and preparation method and application thereof
10/30/2013CN102151331B Polysaccharide-protein conjugate vaccines
10/30/2013CN102112154B IL-1alpha abs and methods of use
10/30/2013CN101932597B Wheat allergens
10/30/2013CN101905022B Stable medicinal composition containing artemisia pollen allergen and preparation method thereof
10/30/2013CN101883856B Influenza virus-like particles (VLPs) comprising hemagglutinin produced within plant
10/30/2013CN101820898B Functional humanization of complementarity determining regions (CDRs)
10/30/2013CN101641374B Binding members for interleukin-6
10/30/2013CN101516912B Antibodies recognizing carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
10/30/2013CN101501072B Antibody molecules which bind human IL-17
10/30/2013CN101495135B Treatment of pain by use of single chain polypeptide fusion protein
10/30/2013CN101478985B Virulence determinant within E2 structural glycoprotein of classical swine fever virus
10/30/2013CN101044242B Tumor specific antibody
10/29/2013US8569473 Pestivirus species
10/29/2013US8569472 Efficient cell culture system for hepatitis C virus genotype 6A
10/29/2013US8569470 Engineered pertactin variants for vaccine use
10/29/2013US8569462 Antibodies specific for TGF-beta and methods for treating thereof
10/29/2013US8569456 Receptor activator of NF-kappaB
10/29/2013US8569332 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
10/29/2013US8569280 Methods for the treatment of multiple myeloma
10/29/2013US8569242 Method of treating degenerative disorders of the nervous system
10/29/2013US8569233 Modified animal erythropoietin polypeptides and their uses
10/29/2013US8568744 Inactivated bacterial cell formulation
10/29/2013US8568743 Inactivated bacterial cell formulation
10/29/2013US8568742 Methods and compositions involving immunostimulatory oligodeoxynucleotides
10/29/2013US8568740 Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
10/29/2013US8568739 Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses
10/29/2013US8568738 Virus-modified bacteria ghosts
10/29/2013US8568735 Immunogenic compositions of Staphylococcus aureus antigens
10/29/2013US8568734 Method for generating immune responses utilizing nucleic acids encoding fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes
10/29/2013US8568733 HER-2/neu fusion proteins
10/29/2013US8568732 Chlamydia antigens
10/29/2013US8568731 Staphylococcus aureus antigenic polypeptides and compositions
10/29/2013US8568730 Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma
10/29/2013US8568728 Beta-glucuronide-linker drug conjugates
10/29/2013US8568727 Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
10/29/2013US8568726 RSV specific binding molecule
10/29/2013US8568725 Method of treating transplant rejection with an anti-CD40 antibody
10/29/2013US8568724 Use of anti-factor XI antibodies for prevention of thrombus formation
10/29/2013US8568723 Method of reducing pruritis using IL-31 monoclonal antibodies
10/29/2013US8568722 High affinity antibody antagonists of interleukin-13 receptor alpha 1
10/29/2013US8568721 Method of treating rheumatoid arthritis with an anti-IL-6R antibody
10/29/2013US8568720 High concentration antibody-containing liquid formulation
10/29/2013US8568719 Antibodies against human respiratory syncytial virus (RSV) and methods of use
10/29/2013US8568718 Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
10/29/2013US8568717 Single domain antibodies capable of modulating BACE activity
1 ... 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 ... 1823